ArticleBlood advances2026

Outcomes for CART as 2L vs 3L vs 4L or beyond in aggressive B-cell lymphoma: real-world evidence from the ABC Consortium.

John S Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.